GlaxoSmithKline Pharmaceuticals Limited, a subsidiary of GSK plc, has announced its entry into oncology in India with the launch of Jemperli (dostarlimab) and Zejula (niraparib).
Jemperli is India’s first and only approved PD-1 immunotherapy for second-line treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced endometrial cancer. Zejula is the only once-daily oral PARP inhibitor approved in India as first-line monotherapy maintenance for advanced ovarian cancer across all biomarker types.
The launch addresses the growing need for specialized cancer treatments, especially as the incidence of gynecological cancers in Indian women is projected to rise significantly by 2045. To support access, GSK is also introducing ‘Phoenix’, a patient support program.
Jemperli, a PD-1 blocking antibody, is indicated for dMMR/MSI-H recurrent or advanced endometrial cancer that has progressed after prior platinum-based chemotherapy. Zejula, a once-daily oral PARP inhibitor, is approved for first-line maintenance treatment in patients with advanced or relapsed epithelial ovarian cancer responding to platinum-based chemotherapy, irrespective of biomarker status.
Both therapies are backed by robust clinical evidence and are approved in over 40 countries, including the US, UK, and EU. In India, GSK is also engaged in ongoing oncology clinical trials to potentially expand the use of dostarlimab to other cancers such as non-small cell lung, head and neck, and colorectal cancer.